Cure Models as a Useful Statistical Tool for Analyzing Survival

被引:163
作者
Othus, Megan [1 ]
Barlogie, Bart [3 ]
LeBlanc, Michael L. [1 ]
Crowley, John J. [2 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98117 USA
[2] Canc Res & Biostat, Seattle, WA USA
[3] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
关键词
ACUTE MYELOID-LEUKEMIA; MULTIPLE-MYELOMA; MIXTURE-MODELS; FRACTION; TRANSPLANTATION; TRIAL; REGRESSION; THERAPY; CANCER;
D O I
10.1158/1078-0432.CCR-11-2859
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Cure models are a popular topic within statistical literature but are not as widely known in the clinical literature. Many patients with cancer can be long-term survivors of their disease, and cure models can be a useful tool to analyze and describe cancer survival data. The goal of this article is to review what a cure model is, explain when cure models can be used, and use cure models to describe multiple myeloma survival trends. Multiple myeloma is generally considered an incurable disease, and this article shows that by using cure models, rather than the standard Cox proportional hazards model, we can evaluate whether there is evidence that therapies at the University of Arkansas for Medical Sciences induce a proportion of patients to be long-term survivors. Clin Cancer Res; 18(14); 3731-6. (C)2012 AACR.
引用
收藏
页码:3731 / 3736
页数:6
相关论文
共 33 条
[1]
ARMITAGE JO, 1989, BLOOD, V73, P1749
[2]
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Vesole, DH ;
Naucke, S ;
Cheson, B ;
Mattox, S ;
Bracy, D ;
Salmon, S ;
Jacobson, J ;
Crowley, J ;
Tricot, G .
BLOOD, 1997, 89 (03) :789-793
[3]
Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].
Barlogie, B ;
Tricot, G ;
Anaissie, E ;
Shaughnessy, J ;
Rasmussen, E ;
van Rhee, F ;
Fassas, A ;
Zangari, M ;
Hollmig, K ;
Pineda-Roman, M ;
Lee, C ;
Talamo, G ;
Thertulien, R ;
Kiwan, E ;
Krishna, S ;
Fox, M ;
Crowley, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030
[4]
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 [J].
Barlogie, Bart ;
Anaissie, Elias ;
van Rhee, Frits ;
Haessler, Jeffrey ;
Hollmig, Klaus ;
Pineda-Roman, Mauricio ;
Cottler-Fox, Michele ;
Mohiuddin, Abid ;
Alsayed, Yazan ;
Tricot, Guido ;
Bolejack, Vanessa ;
Zangari, Maurizio ;
Epstein, Joshua ;
Petty, Nathan ;
Steward, Douglas ;
Jenkins, Bonnie ;
Gurley, Jennifer ;
Sullivan, Ellen ;
Crowley, John ;
Shaughnessy, John D. Jr .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (02) :176-185
[5]
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma [J].
Barlogie, Bart ;
Tricot, Guido J. ;
van Rhee, Frits ;
Angtuaco, Edguardo ;
Walker, Ron ;
Epstein, Joshua ;
Shaughnessy, John D. ;
Jagannath, Sundar ;
Bolejack, Vanessa ;
Gurley, Jennifer ;
Hoering, Antje ;
Vesole, David ;
Desikan, Raman ;
Siegel, David ;
Mehta, Jayesh ;
Singhal, Seema ;
Munshi, Nikhil C. ;
Dhodapkar, Madhav ;
Jenkins, Bonnie ;
Attal, Michel ;
Harousseau, Jean-Luc ;
Crowley, John .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (02) :158-164
[6]
LONG-TERM SURVIVAL IN ACUTE MYELOID-LEUKEMIA - THE-EASTERN-COOPERATIVE-ONCOLOGY-GROUP (ECOG) EXPERIENCE [J].
BENNETT, JM ;
ANDERSEN, JW ;
CASSILETH, PA .
LEUKEMIA RESEARCH, 1991, 15 (04) :223-227
[7]
SURVIVAL CURVE FOR CANCER PATIENTS FOLLOWING TREATMENT [J].
BERKSON, J ;
GAGE, RP .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1952, 47 (259) :501-515
[8]
Bloomfield CD, 1998, CANCER RES, V58, P4173
[9]
A new Bayesian model for survival data with a surviving fraction [J].
Chen, MH ;
Ibrahim, JG ;
Sinha, D .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (447) :909-919
[10]
Bayesian inference for multivariate survival data with a cure fraction [J].
Chen, MH ;
Ibrahim, JG ;
Sinha, D .
JOURNAL OF MULTIVARIATE ANALYSIS, 2002, 80 (01) :101-126